Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (3292 companies, A–Z).
Vistagen reported constructive FDA feedback from a Type C meeting on registrational paths for its lead product candidate, fasedienol, in social anxiety disorder. The company plans to use interim assessments, submit a revised protocol, and focus development on the general SAD population rather than acute treatment alone.
FDA gave constructive feedback on using the Liebowitz Social Anxiety Scale as the primary endpoint in a future Phase 3 study.
Vistagen plans to add interim assessments using eDiaries and qualitative patient surveys and to submit a revised protocol to the FDA.
The company plans to pursue fasedienol for overall, not only acute, treatment of SAD, and cited the FDA's recognition of its reported safety profile.
The filing contains no financial results, and the company states that future FDA feedback may not lead to a successful registrational pathway.
Future Vision II Acquisition Corp. (FVN) received written notice on November 5, 2026, from Nasdaq confirming it has regained compliance with the minimum public holders requirement for continued listing on the Nasdaq Capital Market. Nasdaq said the matter is now closed, so the company is no longer under this listing deficiency.
Notice received November 5, 2026 from Nasdaq's Listing Qualifications Department
Compliance regained with minimum public holders requirement under Nasdaq Listing Rule 5550(a)(3)
Nasdaq stated the matter is closed; the 8-K was signed by CEO and Director Danhua Xu on November 9, 2026
On November 5, 2026, the Public Service Commission of Wisconsin approved rate changes in rate cases filed in April 2026 by Wisconsin Electric Power Company, Wisconsin Gas LLC and Wisconsin Public Service Corporation. The presentation slides attached to the filing list an authorized return on equity of 9.50% and an equity ratio of 53.0%, and say a final written order is expected before year-end.
PSCW approved rate changes on November 5, 2026 for Wisconsin Electric, Wisconsin Gas and Wisconsin Public Service
Authorized return on equity of 9.50% and equity ratio of 53.0%
Earnings sharing: no sharing on the first 15 basis points above the allowed ROE, 50/50 on the next 25 basis points, and 100% to customers beyond 40 basis points
Essential Utilities disclosed that American Water, Essential Utilities and their affiliates filed a Stipulation of Settlement with the New Jersey Board of Public Utilities (NJBPU) on November 2, 2026, in the proceeding to approve the proposed merger. The stipulation was entered into with all parties, including NJBPU staff and the New Jersey Division of Rate Counsel, and is subject to review and approval by the NJBPU. The filing shows progress on regulatory approval, but the merger still requires the NJBPU's approval before it can proceed.
Stipulation of Settlement filed November 2, 2026, with all parties in the NJBPU proceeding
Stipulation posted to the NJBPU website as of November 5, 2026, and remains subject to NJBPU review and approval
Merger agreement with American Water was signed October 26, 2025; Essential Utilities would become a wholly owned subsidiary
Spire Missouri filed a general rate case with the Missouri Public Service Commission on November 2, 2026, requesting a total revenue requirement increase of $228 million. The filing is based on an average fiscal 2028 future test year rate base of $5.1 billion, and the commission has 11 months to review it, with new rates expected by October 2027. For shareholders, the outcome will determine how much of the utility's infrastructure investment is recovered through customer rates.
Total requested revenue increase of $228 million, including $57 million through the Infrastructure System Replacement Surcharge and $171 million in net new revenues
Proposed rates are based on an average fiscal 2028 future test year rate base of $5.1 billion, assuming a 55.0% common equity ratio and 10.5% return on equity
Company estimates the average residential bill would rise about $10 per month (11%) in western Missouri and about $13 per month (15%) in eastern Missouri if approved as filed
Missouri Public Service Commission has 11 months to consider the filing; new rates expected to be effective by October 2027
A Delaware Court of Chancery granted FBB Holdings I's motions and enjoined Destination XL from terminating its merger agreement with FBB while the court makes further expedited determinations. The order is temporary and not a ruling on the merits, and DXL says it believes FBB's claims are without merit and will defend against them.
The Court of Chancery held a hearing on October 29, 2026 and granted both motions after it.
The merger agreement, dated December 11, 2025, allows either party to terminate if the merger is not completed by October 30, 2026.
FBB filed its complaint on October 26, 2026; DXL filed an answer and counterclaims on October 28, 2026.
DXL's preliminary proxy statement was filed July 17, 2026 and amended most recently on October 19, 2026.
Zillow Group entered a settlement agreement on October 27, 2026, to resolve the consolidated securities class action Jaeger v. Zillow Group, Inc. The company will pay $212.5 million in cash into an escrow fund within 20 business days after preliminary court approval, with about $48 million expected to come from insurance proceeds. The settlement is subject to court approval and does not affect the related shareholder derivative actions, which remain pending.
Settlement payment totals $212.5 million, with about $48 million expected from insurance proceeds
Payment due within 20 business days after the court preliminarily approves the settlement
Class covers stock purchases from August 5, 2021, to November 2, 2021; agreement includes no admission of liability
Related shareholder derivative actions remain pending and are not resolved by this settlement
TXNM Energy disclosed that hearing examiners at the New Mexico Public Regulation Commission published a revised procedural schedule for the merger application on October 27, 2026. Evidentiary hearings are set for January 19 to February 1, 2027. TXNM still expects the merger with Troy ParentCo to close in the first half of 2027, but says it cannot predict the outcome.
NMPRC hearing examiners set evidentiary hearings for January 19 to February 1, 2027
The merger still requires NMPRC approval and satisfaction or waiver of customary conditions
TXNM continues to anticipate the merger closing in the first half of 2027
Nasdaq granted Rekor Systems an additional 180 calendar days, until April 26, 2027, to regain compliance with its minimum $1.00 bid price requirement. The notice has no immediate effect, and the common stock continues to trade on The Nasdaq Capital Market under REKR, but the company must close at or above $1.00 for at least ten consecutive business days by that date or face delisting.
Initial compliance period expired October 26, 2026; extension runs to April 26, 2027
Nasdaq first notified the company on April 27, 2026 after the stock closed below $1.00 for 30 consecutive business days
To regain compliance, the closing bid price must be at least $1.00 for ten consecutive business days
If not compliant by April 26, 2027, Nasdaq will issue a delisting notice; a hearing request would not stay trading suspension
Kinetik subsidiary EagleClaw Midstream Ventures agreed on October 23, 2026 to resolve a previously disclosed dispute with Energy Transfer over when an NGL purchase agreement expires. Under the settlement, both parties confirmed the agreement's final day of term is December 31, 2026. The filing notes that a related litigation over two Energy Transfer agreements, including this one, remains pending adjudication.
Settlement agreed October 23, 2026 between EagleClaw Midstream Ventures and Energy Transfer GC NGL Product Services
ECMV NGL purchase agreement final day of term confirmed as December 31, 2026
The agreement is one of two Energy Transfer agreements subject to previously disclosed litigation, which awaits adjudication
Medalist Diversified filed a Certificate of Correction with Maryland on October 19, 2026, stating that a charter amendment approved at its June 16, 2026 annual meeting is of no force or effect. The company said the amendment, which restricted certain stock transfers to protect net operating loss and net capital loss tax benefits, did not receive the required stockholder vote. The board says it intends to seek stockholder approval again at a special meeting.
Certificate of Correction filed with Maryland SDAT on October 19, 2026
Charter Amendment originally filed with SDAT on June 17, 2026, after June 16, 2026 annual meeting
Amendment would have limited transfers that raise a holder's stake from under 4.9% to 4.9% or more
Over 95% of votes cast supported the proposal, but the required vote was not met
Collegium Pharmaceutical agreed on October 15, 2026 to settle all disputes with Grünenthal GmbH, including a patent infringement lawsuit over the Nucynta ER authorized generic. As part of the settlement, the company's license agreement with Grünenthal was terminated in its entirety, and the company made a $17 million payment, after which no further royalties are due under that license.
Settlement agreement dated October 15, 2026 resolves all disputes, including the Nucynta Litigation filed in February 2026 in the District of New Jersey
Collegium paid Grünenthal $17 million; the Grünenthal License terminated effective October 15, 2026
No further royalties will be due under the Grünenthal License; Grünenthal assigned certain Nucynta-related patents to Collegium and moved to dismiss the lawsuit
BioCardia said the FDA has accepted its revised De Novo pre-submission package for marketing clearance of its Helix catheter, and it expects FDA substantive review and a meeting this quarter. The filing does not report any financial results, and clearance is not yet granted, so the update is a regulatory milestone rather than a change in reported financial performance.
FDA accepted the revised De Novo pre-submission package, announced October 19, 2026
Company met with FDA in May 2026 and FDA confirmed and accepted the meeting minutes in August 2026
Revised package was re-submitted in September 2026 and BioCardia expects FDA substantive review and a meeting this quarter
Company cites clinical data from fifteen clinical trials including nearly five hundred patients
Ultragenyx and Baylor Research Institute settled patent litigation with Navinta LLC over patents covering DOJOLVI oral liquid. Navinta will receive a non-exclusive, royalty-free license to market a generic version starting January 1, 2033, which would extend to July 1, 2033 if pediatric exclusivity is granted. The filing does not give a financial impact, and other ANDA patent litigation on DOJOLVI remains pending.
Settlement with Navinta LLC resolves patent litigation filed in the U.S. District Court for the District of New Jersey
Navinta's generic DOJOLVI license begins January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted
Similar patent litigation against other ANDA filers remains pending in the same court
Settlement agreement will be submitted to the FTC and the U.S. Department of Justice
Conduent and two subsidiaries entered a class action settlement agreement on October 16, 2026, to resolve a consolidated lawsuit over the company's January 2025 cybersecurity incident. The settlement requires a non-reversionary $80 million fund and takes effect only if the U.S. District Court for the District of New Jersey approves it. The company says it maintains cyber insurance and does not expect a material impact on its financial position, results of operations or cash flows.
Company will fund $80 million into a non-reversionary settlement fund, its total monetary obligation under the agreement
Fund covers class member recovery, credit and medical data monitoring, plaintiffs' counsel fees and administration costs
Settlement releases the company, affected clients and their customers from claims tied to the cyber incident upon final approval
Agreement is not an admission of fault and remains subject to Court approval
On October 15, 2026, Sanara MedTech and MiMedx each received a Second Request from the Federal Trade Commission as part of its review of the proposed merger in which Sanara would become a wholly-owned subsidiary of MiMedx. Under the Hart-Scott-Rodino Act, the Second Request extends the waiting period until 30 days after the parties substantially comply, so closing is likely to take longer, and completion still depends on regulatory and other conditions.
FTC issued a Second Request to Sanara and MiMedx on October 15, 2026.
The Second Request extends the HSR Act waiting period until 30 days after substantial compliance, unless extended or terminated earlier.
Completion remains subject to HSR waiting period expiration and other closing conditions in the Merger Agreement.
The filing does not state a expected closing date or any financial figures for the deal.
Nathan's Famous said it is voluntarily supplementing its definitive proxy statement for the proposed $102.00-per-share merger with Smithfield Foods, after two stockholder lawsuits and fifteen demand letters challenged the proxy's disclosures. The company and its board deny the claims, but say the supplements aim to moot the disclosure claims and reduce litigation costs and risks before the October 23, 2026 special meeting of stockholders.
Two lawsuits were filed September 30, 2026, in the Supreme Court of the State of New York against the company and its board, and seek to enjoin the merger.
Purported stockholders delivered fifteen demand letters and two Section 220 books-and-records demands under Delaware law.
The supplemental disclosures cover executive retention discussions with the buyer and Jefferies LLC's selected companies analysis.
The special meeting of stockholders is scheduled for October 23, 2026; the merger consideration is $102.00 per share.
Quoin Pharmaceuticals said on October 14, 2026 that the European Medicines Agency granted Orphan Drug Designation to its lead product candidate QRX003 for treating Peeling Skin Syndrome. If QRX003 is approved for marketing by the EMA, the company would receive 10 years of market exclusivity in Europe for similar medicines for this indication, and the company plans to start the first-ever formal clinical study for the condition before year end.
EMA granted Orphan Drug Designation to QRX003 for Peeling Skin Syndrome, announced October 14, 2026
Designation brings scientific advice on study protocols, various fee reductions and access to EU grants
If approved by the EMA, QRX003 would receive 10 years of market exclusivity in Europe for this indication
The company intends to initiate the first-ever formal clinical study for Peeling Skin Syndrome before year end
SS Innovations said it submitted its response to an FDA request for additional information on its 510(k) application for the SSi Mantra surgical robotic system on October 5, 2026. The response includes final data from an expanded human clinical and human factors validation study and a bridging study, and the company expects the FDA to complete its review in the first quarter of 2027. The filing describes a regulatory milestone toward U.S. market entry but gives no financial results or timing guarantees.
Response to the FDA's request for additional information was submitted on October 5, 2026.
The response includes final data from an expanded human clinical and human factors validation study and a bridging study completed in August 2026 at Hospital Internacional de Colombia in Bucaramanga.
The company expects the FDA to complete its review of the response and the 510(k) submission in the first quarter of 2027.
The 510(k) submission covers the initial indication of cholecystectomy (gallbladder removal).
The SEC approved a Nasdaq rule requiring listed companies to maintain at least $5,000,000 in market value of listed securities, and Artelo was among about 180 Nasdaq companies initially flagged as below that threshold. The rule is now under a temporary stay, and the company does not know how long the stay will last or whether the rule will be reinstated in its current form.
SEC approved Nasdaq's $5M MVLS rule on July 22, 2026; a temporary stay was announced July 29, 2026.
On October 5, 2026, the SEC published Nasdaq's proposed change tying the rule's operative date to the end of the stay; comments are due October 29, 2026.
Artelo says it may consider raising capital through its at-the-market equity program or other financings if the rule applies to it, but has not committed to any course of action.
American Express and its bank subsidiary consented to orders from the Federal Reserve and the Office of the Comptroller of the Currency to resolve regulatory reviews of parts of its financial crimes compliance program. The bank unit also agreed to pay a $350 million civil money penalty, part of which was already reserved for in prior periods. The company says the penalty does not affect its 2026 guidance, and the orders impose no asset cap and are not expected to affect 2027 guidance.
Consent orders issued October 8, 2026 by the Federal Reserve and the OCC resolve previously disclosed reviews of financial crimes compliance.
American Express National Bank agreed to pay a $350 million civil money penalty to the OCC.
A portion of the penalty was reserved for in prior periods; the company says it does not affect full-year 2026 guidance.
The orders do not impose an asset cap, and remediation costs are not anticipated to affect 2027 guidance.
Perspective Therapeutics (NYSE American: CATX) announced on October 8, 2026 that the U.S. Food and Drug Administration granted Fast Track Designation for PSV359 for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. The filing says the designation is intended to facilitate development and expedite review, and that PSV359 is in an ongoing Phase 1/2a study, but it does not describe any financial effect.
FDA granted Fast Track Designation for PSV359 on or before October 8, 2026, per the press release dated October 8, 2026.
The designation covers adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.
PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in an ongoing Phase 1/2a study (NCT06710756).
The press release is filed as Exhibit 99.1; the filing reports no financial figures.
A Florida state court set a December 14, 2026 hearing to decide whether to approve a proposed settlement of a shareholder derivative lawsuit and related derivative actions and demands brought on NextEra Energy's behalf. The settlement includes a $15.5 million cash payment to the company and corporate governance reforms, and it resolves claims that would otherwise continue against the individual defendants. Shareholders were notified of the proposal and their right to be heard at the hearing.
Court order dated September 22, 2026 set the Settlement Hearing for December 14, 2026 at 3:00 p.m.
Settlement consideration includes a $15.5 million cash payment to NextEra Energy and governance reforms set out in Exhibit A.
The Revised Stipulation of Settlement is dated July 29, 2026 and replaces the original stipulation dated June 11, 2026.
The hearing will also consider an agreed award of attorneys' fees and expenses for shareholder counsel.
TELA Bio, Inc. received a letter from The Nasdaq Stock Market on October 5, 2026, stating that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market, and the matter is now closed. The company's common stock continues to trade on the Nasdaq Global Market under the symbol TELA, so shareholders face no change in listing status.
Nasdaq letter received October 5, 2026 confirms compliance with the minimum bid price requirement under Listing Rule 5450(a)(1)
Nasdaq matter is closed
Common stock continues to trade on the Nasdaq Global Market under the symbol TELA
Endovia Health Sciences announced that the FDA's Center for Veterinary Medicine determined CannEpil qualifies as a minor use for controlling bone cancer pain in dogs, making it eligible to pursue the conditional approval pathway. The product remains investigational and is not approved or conditionally approved, and the company has not given revenue or financial figures in this filing.
FDA Center for Veterinary Medicine determined CannEpil qualifies as a minor use under the MUMS program
Endovia and Lupvindol are scheduled to meet the FDA for a Pre-Submission Conference on November 19, 2026
Company is working toward a potential veterinary launch in 2027, subject to FDA approval
American Battery Technology Company received approval from the U.S. Department of Commerce's Bureau of Industry and Security for a license to export recycled black mass, allowing sales of up to $100 million under specified terms. The license follows newly enacted federal export controls on critical battery materials, and the company says it supports current operations and its market position.
BIS approved a license allowing sales of up to $100 million of recycled black mass material
The approval follows the implementation of recently enacted federal export controls on critical battery materials
The press release, dated October 1, 2026, cites over 400% year-over-year revenue growth and references the company's fiscal year 2026 results
The filing is a Form 8-K under Item 8.01 with the press release attached as Exhibit 99.1
BioCardia reported it has completed a revised Pre-Submission to the FDA's Center for Devices and Radiological Health for approval of its Helix Catheter, which is used for delivering therapeutic and diagnostic agents to the heart. The filing says FDA agreed in May 2026 that there are two pathways to marketing clearance and raised no concerns about Helix safety data or device performance, so the revised submission is a regulatory step toward a possible market clearance.
Revised pre-submission completed under the Q-Submission program, reported October 1, 2026.
FDA met with the company in May 2026 and said there are two pathways for Helix marketing clearance.
FDA targets an initial acceptance or refusal review within 15 calendar days and written feedback or a meeting within 70 calendar days.
The company cites clinical data from 15 clinical trials including nearly 500 patients.
BioMarin entered into a Settlement and License Agreement with Ascendis Pharma on September 24, 2026, replacing an August 2026 binding term sheet. Ascendis receives a non-exclusive license to BioMarin patents covering TransCon CNP (navepegritide, Yuviwel), and BioMarin receives royalties on net sales until May 2030. The filing says the parties will dismiss all pending litigation between them over the patents, and it does not disclose dollar amounts.
Agreement dated September 24, 2026, deemed effective August 28, 2026, and supersedes the term sheet reported on August 31, 2026
Royalty of 20% of annual net sales in the United States and 18% in the EU, Brazil and South Korea, until May 2030
Pending litigation between the parties relating to the BioMarin patent rights to be dismissed with prejudice
Ascendis agreed not to challenge BioMarin's patent rights; no dollar figures disclosed
DBV Technologies said it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its VIASKIN Peanut Patch in children with peanut allergy aged 4 through 7 years, and has requested Priority Review. The application is supported by results from the Phase 3 VITESSE trial, which enrolled 654 children, and the FDA previously granted the patch Breakthrough Therapy Designation. The filing reports a regulatory milestone, not revenue or approval, and the company states the product has not been authorized for sale in any country.
BLA submitted to the FDA for VIASKIN Peanut Patch in children aged 4 through 7 years, announced September 29, 2026
DBV has requested Priority Review; the FDA previously granted Breakthrough Therapy Designation
VITESSE Phase 3 trial enrolled 654 children, randomized 2:1 to active patch or placebo
The company states the product has not been authorized for sale in any country
Gossamer Bio received a Nasdaq letter on September 25, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement, closing the matter. The company had completed a 1-for-80 reverse stock split on September 10, 2026, with split-adjusted trading beginning September 11, 2026. The filing shows the listing issue is resolved, but it does not report any change to financial results.
Nasdaq letter dated September 25, 2026 confirms compliance with the minimum bid price rule under Nasdaq Listing Rule 5450(a)(1)
The matter followed a Nasdaq letter received April 8, 2026, after the stock failed to trade at $1.00 or more for 30 consecutive business days
1-for-80 reverse stock split effective September 10, 2026; split-adjusted trading began September 11, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.